BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 14751359)

  • 1. Treatment options for localized prostate cancer: quality-adjusted life years and the effects of lead-time.
    Bhatnagar V; Stewart ST; Bonney WW; Kaplan RM
    Urology; 2004 Jan; 63(1):103-9. PubMed ID: 14751359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum PSA evaluations during salvage radiotherapy for post-prostatectomy biochemical failures as prognosticators for treatment outcomes.
    Do T; Dave G; Parker R; Kagan AR
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1220-5. PubMed ID: 11483332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radical retropubic prostatectomy in men younger than 45 years diagnosed during early prostate cancer detection program.
    Varkarakis J; Pinggera GM; Sebe P; Berger A; Bartsch G; Horninger W
    Urology; 2004 Feb; 63(2):337-41. PubMed ID: 14972485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival.
    Parker C; Muston D; Melia J; Moss S; Dearnaley D
    Br J Cancer; 2006 May; 94(10):1361-8. PubMed ID: 16641912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of treatment on quality of life among men with clinically localized prostate cancer.
    Schapira MM; Lawrence WF; Katz DA; McAuliffe TL; Nattinger AB
    Med Care; 2001 Mar; 39(3):243-53. PubMed ID: 11242319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer.
    Petrovich Z; Lieskovsky G; Langholz B; Jozsef G; Streeter OE; Skinner DG
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):600-9. PubMed ID: 12062603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invasion of seminal vesicles by adenocarcinoma of the prostate: PSA outcome determined by preoperative and postoperative factors.
    Bloom KD; Richie JP; Schultz D; Renshaw A; Saegaert T; D'amico AV
    Urology; 2004 Feb; 63(2):333-6. PubMed ID: 14972484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
    Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
    J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary radiotherapy versus radical prostatectomy for high-risk prostate cancer: a decision analysis.
    Parikh R; Sher DJ
    Cancer; 2012 Jan; 118(1):258-67. PubMed ID: 21720990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of outcome after radical prostatectomy in men with organ-confined Gleason score 8 to 10 adenocarcinoma.
    Rioux-Leclercq NC; Chan DY; Epstein JI
    Urology; 2002 Oct; 60(4):666-9. PubMed ID: 12385930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
    Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decision analyses in consideration of treatment strategies for patients with biochemical failure after curative therapy on clinically localized prostate cancer in the prostate-specific antigen era.
    Shimizu F; Igarashi A; Fukuda T; Kawachi Y; Minowada S; Ohashi Y; Fujime M
    Jpn J Clin Oncol; 2007 Oct; 37(10):763-74. PubMed ID: 17956899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?
    Choo R; Hruby G; Hong J; Hong E; DeBoer G; Danjoux C; Morton G; Klotz L; Bhak E; Flavin A
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):674-80. PubMed ID: 11849789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate.
    D'amico AV; Tempany CM; Schultz D; Cormack RA; Hurwitz M; Beard C; Albert M; Kooy H; Jolesz F; Richie JP
    Urology; 2003 Dec; 62(6):1063-7. PubMed ID: 14665356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts.
    Malaeb BS; Rashid HH; Lotan Y; Khoddami SM; Shariat SF; Sagalowsky AI; McConnell JD; Roehrborn CG; Koeneman KS
    Urol Oncol; 2007; 25(4):291-7. PubMed ID: 17628294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minute focus of prostate cancer on needle biopsy: correlation with radical prostatectomy specimen.
    Montanari E; Del Nero A; Gazzano G; Mangiarotti B; Bernardini P; Longo F; Cordima G; Itri E
    Arch Ital Urol Androl; 2009 Mar; 81(1):9-12. PubMed ID: 19499751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zonal location of prostate cancer: significance for disease-free survival after radical prostatectomy?
    Augustin H; Hammerer PG; Blonski J; Graefen M; Palisaar J; Daghofer F; Huland H; Erbersdobler A
    Urology; 2003 Jul; 62(1):79-85. PubMed ID: 12837427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
    Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR
    JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
    Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
    Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.